Ai întrebări despre autism, ADHD, anxietate sau depresie? Găsești ghiduri clare, verificate de specialiști. Acum, acces gratuit.
This cross-sectional study validated a self-report questionnaire (EST-Q) to assess perceived seizure triggers in 100 adults with epilepsy from Brazil. The seven-item core module showed adequate internal consistency for group-level research but insufficient reliability for individual clinical decisions, with exploratory factor analysis supporting a predominantly unidimensional structure.
This study demonstrates that huntingtin protein levels affect the occurrence of a spontaneous seizure disorder in FVB/N mice, with reduced huntingtin increasing seizure frequency while overexpression prevents seizures entirely. The findings raise important considerations for huntingtin-lowering therapies being tested for Huntington disease, suggesting potential adverse effects on seizure susceptibility as a consequence of reduced wild-type huntingtin levels.
This retrospective study analyzed German national health insurance records to assess epilepsy treatment pathways and guideline adherence, identifying a 0.67% national prevalence with 36% of patients classified as drug-refractory. The research validated hospital-based epilepsy center data against national databases to evaluate timely specialist escalation and optimal treatment recommendations.
This systematic literature review examined how seizure freedom is defined and operationalized across clinical trials, regulatory evaluations, and health technology assessments for epilepsy treatments. The review found significant variability in seizure freedom definitions based on patient population, seizure type, clinical setting, and analytical methods, highlighting the need for standardized definitions to improve treatment outcome comparability.
This mechanistic review examines how metformin, an FDA-approved antidiabetic agent, may reduce seizures in treatment-resistant epilepsy through multiple pathways including AMPK activation, mTOR inhibition, and BDNF enhancement with neuroprotective effects. The authors propose metformin as a potential adjunctive agent to conventional anti-epileptic drugs, supported by preclinical evidence of reduced neuroinflammation and seizure severity.